Acute Myeloid Leukemia
Conditions
Keywords
Acute myeloid leukemia, monotherapy, SKLB1028
Brief summary
Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to evaluate the side effects,tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.
Detailed description
It is an open,multicenter,queue extension study designed to characterize the efficacy and safety of different administration regimens of SKLB1028 capsules in patients with recurrent/refractory acute myeloid leukemia with FLT3 mutation. Divided into three dose groups,150mg BID,200mg BID,300mg QD. The main end point is total remission rate (ORR), total survival time (OS), progress-free survival time (PFS), remission duration, FLT3 suppression rate, competitive parameters, safety (incidence of adverse events).
Interventions
DRUGSKLB1028 150mg bid
150mg oral administration twice a day
DRUGSKLB1028 200mg bid
200mg oral administration twice a day
DRUGSKLB1028 300mg qd
300mg oral administration once a day
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
The dose was initiated at 150 mg bid and after completion of the safety tolerance,200 mg bid was performed.300mg qd is safe and tolerant at phase 1 ,so the other participants were able to conduct the 300 mg qd test group when the safety tolerance.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Volunteer and sign informed consent forms 2. Male or female Chinese patients, age ≥ 18 years old 3. In patients with primary or secondary aml diagnosed according to (who) classification of the World Health Organization, patients with FLT3 mutation were detected by leukemia cell gene, and refractory aml; after at least one cycle of induction treatment of: a) met any of the following conditions. B) recurrent aml; after at least one cycle of induction therapy 4. Ecog score 0-3 5. Expected survival time greater than 3 months 6. The study drug was at least 2 weeks apart from prior cytotoxic chemotherapy (except for hydroxyl groups), or at least 5 half-lives or 4 weeks with prior non-cytotoxic chemotherapy agents, short-term 7. Upper limit of normal value of serum creatinine ≤ 1.5 times 8. The upper limit of the normal value of total bilirubin ≤ 1.5 times, except for gilbert's syndrome and leukemia involving organs. 9. Upper limit of serum AST,ALT ≤ 3.0 times normal value, except where leukemia involves organs 10. The subjects of childbearing age agreed to take effective contraceptives during the treatment and 6 months after the completion of the treatment.
Exclusion criteria
1. Diagnosed acute promyelocytic leukemia 2. Recent symptomatic central neurosystemic leukemia 3. There are grade 2 or more non-hematological toxicity caused by previous chemotherapy 4. Bone marrow transplants within 100 days of the study 5. Uncontrollable active infections (acute or chronic fungi, bacteria, viruses, or other infections) 6. Major surgical treatment of major organs was performed in the first 4 weeks of the study 7. Radiotherapy was performed within 4 weeks before entering the study 8. Cardiac ejection fraction below 50% or below the lower limit of normal value; patients with prolonged history of qtc (male \> 450 Ms, female \> 470ms); severe history of heart 9. Hiv positive 10. Active hepatitis B virus infection (hepatitis B virus surface antigen positive and hepatitis B dna quantity ≥ 1 × 10\^3copies/ml), hepatitis C virus infection or other liver diseases 11. Pregnant or lactating women 12. There are serious diseases or complications, or diseases that the researchers determine may endanger the safety of the patient or interfere with the study 13. Patients who are not considered to be able to enter the study 14. Treatment is currently under way in another clinical trial or in another clinical trial within four weeks of the commencement of SKLB1028 treatment 15. Patients who have previously received sklb1028 or other FLT3 inhibitors (midostaurin,gilteritinib, quizartinib)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total remission rate (ORR) | Evaluation at the end of each cycle(a cycle is 28 days) of administration and at the end of the study (assessed up to approximately 24 months) | Complete remission (CR) + CR with incomplete hematologic recovery (CRi) + complete molecular remission (CRm) + partial remission（PR） |
Secondary
| Measure | Time frame |
|---|---|
| Total survival time (OS) | 30 days after last subject discontinues treatment (assessed up to approximately 24 months) |
| CR mitigation duration (DoR-CR) | Time from the date at which the patient's objective status is first noted to be a CR to the earliest date progression is documented (assessed up to approximately 24 months |
| FLT3 inhibition rate | Evaluation when the patient's efficacy was evaluated as CR (assessed up to approximately 24 months) |
| Incidence of adverse events | From the start of the study treatment to the end of the study treatment(Within 4 weeks after the last administration) |
| Progression-free survival time (PFS) | Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death |
| 12-lead ECG | From the start of the study treatment to the end of the study treatment(Within 4 weeks after the last administration) |
| physical examination | From the start of the study treatment to the end of the study treatment(Within 4 weeks after the last administration) |
| laboratory examination | From the start of the study treatment to the end of the study treatment(Within 4 weeks after the last administration) |
| Vital signs | From the start of the study treatment to the end of the study treatment(Within 4 weeks after the last administration) |
Countries
China
Outcome results
None listed